跳到正文
原文
MedTech Dive 器械媒体· Nick Paul Taylor·· 3 小时前AI 评分45

Abbott 开始 Encantor 经导管主动脉瓣植入系统临床试验

Abbott starts trial of Encantor transcatheter aortic valve

AI 导读

Abbott 已启动 VOYAGER CE 临床试验,评估其 investigational Encantor 经导管主动脉瓣植入系统在欧洲和澳大利亚的 300 名症状性重度主动脉瓣狭窄患者中的效果。该系统采用软件引导和球囊扩张设计,旨在为医生提供更大的控制和手术信心。Abbott 计划在不久的将来在美国启动关键性试验。

正文

This audio is auto-generated. Please let us know if you have feedback.

Dive Brief:

  • Abbott said Thursday it has started the VOYAGER CE clinical trial of its investigational Encantor transcatheter aortic valve implantation system.
  • The trial is evaluating the software-guided, balloon-expandable system in up to 300 symptomatic severe aortic stenosis patients in Europe and Australia. Abbott plans to start a pivotal trial in the U.S. in the coming months.
  • Encantor’s balloon-expansion system differentiates it from Abbott’s Navitor TAVI system, which uses a self-expanding valve. Abbott sees the devices as complementary.

Dive Insight:

Physicians treating symptomatic severe aortic stenosis have access to balloon- and self-expanding valves. Edwards Lifesciences’ Sapien valves use a balloon-expandable frame, while Medtronic’s Evolut devices are self-expanding. The Food and Drug Administration approved Abbott’s self-expanding Navitor valve in 2023.

“Physicians continue to seek technologies that make procedures more predictable and allow treatment to be tailored to individual patients,” Didier Tchétché, a physician and co-principal investigator of Abbott’s trial, said in a statement. “Encantor’s balloon-expandable design and software-guided approach are intended to give physicians greater control and procedural confidence.”

Encantor crimps the new heart valve on a deflated surgical balloon, which is inserted into the body via a catheter in a groin artery. Once the balloon reaches the diseased aortic valve in the heart, the physician customizes the valve’s expansion to the patient’s anatomy using software-guided deployment. The balloon is then deflated and removed, leaving the replacement valve in place. 

Macquarie University in Sydney, Australia, recently enrolled the first patient in VOYAGER CE. Abbott is running the single-arm study to assess Encantor’s effect on the number of deaths and strokes in the 12 months after treatment. The company plans to use the results to seek approval for the device in Europe and Australia. 

Abbott began VOYAGER CE after seeing six-month results from an early feasibility study of the device. The company will share the data on Encantor at PCR London Valves 2026, which begins on Sunday.

来源:MedTech Dive 器械媒体 · medtechdive.com